Holen Sie sich die Stockscreener-App
28.04
0.07%
-0.02
Handel nachbörslich:
28.04
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$28.06
Offen:
$28.22
24-Stunden-Volumen:
1.92M
Relative Volume:
0.83
Marktkapitalisierung:
$4.63B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
14.38
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
-2.03%
1M Leistung:
-4.40%
6M Leistung:
-5.81%
1J Leistung:
-8.81%
1-Tages-Spanne:
$27.85
$28.52
1-Wochen-Bereich:
$27.53
$29.35
52-Wochen-Spanne:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
28.04 | 4.63B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
122.25 | 54.31B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.47 | 45.90B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.86B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.06 | 34.53B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
510.94 | 21.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-11 | Eingeleitet | Truist | Buy |
| 2025-09-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
BlackRock increases stake in Alkermes to 17.04% - Investing.com
Frazier Life Sciences Management L.P. Boosts Stock Position in Alkermes plc $ALKS - MarketBeat
EcoR1 Capital LLC Makes New Investment in Alkermes plc $ALKS - MarketBeat
Retail Surge: Why global investors buy Alkermes plc 8AK stockCEO Change & Expert Curated Trade Ideas - moha.gov.vn
History Review: Will Alkermes plc 8AK stock test record highs in 2025Watch List & High Conviction Investment Ideas - moha.gov.vn
BlackRock increases stake in Alkermes to 17% By Investing.com - Investing.com South Africa
BlackRock increases stake in Alkermes to 17% - Investing.com
REGBlackRock GroupSAR6ALKERMES PLC - TradingView — Track All Markets
Avadel Pharmaceuticals Shares Climb on $2.1 Billion Acquisition by Alkermes - MSN
Analyst Upgrade: How Alkermes plc stock performs after earningsQuarterly Risk Review & Reliable Intraday Trade Plans - moha.gov.vn
Stempoint Capital LP Acquires 158,772 Shares of Alkermes plc $ALKS - MarketBeat
First Trust Advisors LP Has $39.98 Million Stock Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes, Avadel Pharmaceuticals merger gets HSR clearance in US - MLex
Avadel Pharmaceuticals Acquisition by Alkermes Advances - TradingView — Track All Markets
Are Investors Undervaluing Alkermes (ALKS) Right Now? - sharewise.com
(ALKS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Schroder Investment Management Group Invests $1.39 Million in Alkermes plc $ALKS - MarketBeat
Insider Selling: Alkermes (NASDAQ:ALKS) EVP Sells 3,748 Shares of Stock - MarketBeat
Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid - MSN
Norges Bank Invests $53.33 Million in Alkermes plc $ALKS - MarketBeat
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
VP Hopkinson Sells 3,748 ($112.4K) Of Alkermes PLC [ALKS] - TradingView — Track All Markets
Avadel Pharmaceuticals plc and Alkermes plc Announce Proposed Transaction for Acquisition - Quiver Quantitative
Announcement relating to despatch of Rule 15 proposal - The Manila Times
Avadel (NASDAQ: AVDL) sends Rule 15 proposal to equity holders in Alkermes deal - Stock Titan
Capital Fund Management S.A. Makes New $1.14 Million Investment in Alkermes plc $ALKS - MarketBeat
Will Alkermes plc (8AK) stock sustain bullish trend into 2025Fed Meeting & Smart Money Movement Tracker - Newser
ALKS: Elixirxton demonstrates strong efficacy, safety, and dosing flexibility for narcolepsy and hypersomnolence - TradingView
Avadel Pharmaceuticals Announces Mailing of Definitive Proxy Statement Regarding Proposed Acquisition by Alkermes - Quiver Quantitative
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting - Benzinga
Avadel (Nasdaq: AVDL) mails proxy, sets Jan. 12 scheme and EGM on Alkermes deal - Stock Titan
VP Hopkinson Files To Sell 3,748 Of Alkermes PLC [ALKS] - TradingView
Mackenzie Financial Corp Acquires 53,323 Shares of Alkermes plc $ALKS - MarketBeat
Evercore Healthcare Conference - marketscreener.com
How Alkermes plc (8AK) stock valuation compares with sectorQuarterly Profit Report & Daily Profit Focused Screening - Newser
Is Alkermes plc (8AK) stock a safe buy pre earningsMarket Growth Summary & Real-Time Sentiment Analysis - Newser
Insider Selling: Alkermes (NASDAQ:ALKS) EVP Sells 4,000 Shares of Stock - MarketBeat
Regeneron, Tessera to advance gene editing therapy for AATD: Deals Report - biocentury.com
How supply chain issues affect Alkermes plc stockPortfolio Performance Report & Real-Time Stock Movement Alerts - Newser
Should Alkermes (ALKS) Investors Reassess Prospects After Raised 2025 Guidance and Strong Q3 Results? - Yahoo Finance
Is Alkermes plc (8AK) stock among top earnings playsQuarterly Trade Review & Real-Time Volume Surge Alerts - Newser
Insider Sell: Craig Hopkinson Sells 4,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Alkermes plc. Officer Sells 4,000 Shares - TradingView
VP Hopkinson Sells 4,000 ($117.2K) Of Alkermes PLC [ALKS] - TradingView
Avadel Pharmaceuticals plc Announces Scheme Meeting for Alkermes Acquisition Proposal - Quiver Quantitative
Avadel Pharmaceuticals (Nasdaq: AVDL) to hold Scheme and EGM on Alkermes takeover Jan. 12 - Stock Titan
Rhumbline Advisers Purchases 17,660 Shares of Alkermes plc $ALKS - MarketBeat
Legal & General Group Plc Sells 17,227 Shares of Alkermes plc $ALKS - MarketBeat
Loomis Sayles & Co. L P Sells 330,389 Shares of Alkermes plc $ALKS - MarketBeat
JPMorgan Chase & Co. Trims Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes plc $ALKS Shares Sold by Ensign Peak Advisors Inc - MarketBeat
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.66%
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):